NCT00187707View on ClinicalTrials.gov

Influence of Intestinal Transporter Genetic Variants on the Bioavailability of Gabapentin

NACompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

January 31, 2007

Study Completion Date

August 31, 2008

Conditions
Healthy
Interventions
DRUG

Gabapentin

Subjects will take a single dose of 400 mg of gabapentin

Trial Locations (1)

94143

San Francisco General Hospital, San Francisco

All Listed Sponsors
lead

University of California, San Francisco

OTHER

NCT00187707 - Influence of Intestinal Transporter Genetic Variants on the Bioavailability of Gabapentin | Biotech Hunter | Biotech Hunter